
|Videos|November 4, 2021
Controlling ACE and ARB Dosing Can Benefit Treatment of Chronic Kidney Disease
Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, discusses how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Advertisement
In a Pharmacy Times® interview, Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, spoke about his 2021 ASN Kidney Week presentation on the submaximal dose of angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blockers (ARB) for individuals with proteinuria.
He discussed how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
2
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
3
Olezarsen Receives FDA Approval to Reduce Triglycerides, Risk of Acute Pancreatitis in Severe Hypertriglyceridemia
4
ADA 2026: Diabetes Technology Innovations Expand Beyond Traditional CGM Use
5






















































































































